Kansas University Joins PTXs AML Trial
Filed with ASX · · 2 pages · English
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- FDA Grants Orphan Drug Designation for PTX-200 in AML
- March 2017 Appendix 4C - Quarterly
- Successful Completion of Phase 1b Breast Cancer Trial
- Three Additional US Patents Granted
- First Cohort Successfully Completed in Phase 1b/2 AML Trial
Later from Prescient Therapeutics
- European Patent Granted for PTX-200
- PTX Broker Presentation
- Clinical Trial Update
- Novel PTX-100 Cancer Approach Published in Nature
- June 2017 Appendix 4C - Quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics